Neue Aspekte der renalen Osteopathie - Deutsche Therapieergebnisse mit selektiven Vitamin-D-Rezeptor-Aktivatoren

Literatur

• 1 Block GA, Klassen PS, Lazarus JM. et al. . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.  J Am Soc Nephrol. 2004;  15 2208-2218
• 2 Kalantar-Zadeh K, Kuwae N, Regidor DL. et al. . Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.  Kidney Int. 2006;  70 771-780
• 3 Kates DM, Sherrard DJ, Andress DL.. Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure.  Am J Kidney Dis. 1997;  30 809-813
• 4 Martinez I, Saracho R, Montenegro J, Llach F.. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism.  Nephrol Dial Transplant. 1996;  11 22-28
• 5 Martinez I, Saracho R, Montenegro J, Llach F.. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure.  Am J Kidney Dis. 1997;  29 496-502
• 6 Slatopolsky E, Weerts C, Thielan J. et al. . Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.  J Clin Invest. 1984;  74 2136-2143
• 7 Sprague SM, Llach F, Amdahl M, Taccetta C. et al. . Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.  Kidney Int. 2003;  63 1483-1490
• 8 Teng M, Wolf M, Ofsthun MN. et al. . Activated injectable vitamin D and hemodialysis survival: a historical cohort study.  J Am Nephrol. 2005;  16 1115-1125
• 9 Teng M, Wolf M, Lowrie E. et al. . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.  N Engl J Med. 2003;  349 446-456